Emmaus Life Sciences Inc (EMMAW) Growth Rates Comparisons to Major Pharmaceutical Preparations Industry, Sector, Market. Sales, Income, EPS
CSIMarket
 
Emmaus Life Sciences Inc   (EMMAW)
 

Emmaus Life Sciences Inc Growth Comparisons

Select each growth Category to receive further Information





EMMAW Revenue Growth Rate Comparisons Company Industry Sector S&P 500
Y / Y Revenue Growth (Q4 MRQ) -29.68 % 7.99 % 8.07 % 9.17 %
Q / Q Revenue Growth (Q4 MRQ) 36.74 % 1.44 % 1.81 % 4.22 %
Y / Y Revenue Growth (for 12 months ending Q4 TTM) -39.43 % 7.47 % 7.04 % %
Sequential Revenue Growth (for 12 months ending Q4 TTM) -11.79 % 4.22 % 3.51 % 2.08 %
Revenue 5 Year Average Growth -11.68 % 7.41 % 8.65 % 10.59 %


EMMAW's Growth Comparisons in IV. Quarter 2025




Emmaus Life Sciences Inc 's Revenue were slashed by -29.68% in the fourth quarter 2025 from the same quarter a year ago, to $ 4 millions, while sales in theMajor Pharmaceutical Preparations industry grew by 7.99%, and underperformed the 8.07% Revenue growth in the Healthcare sector. Weak fourth quarter sales, in Major Pharmaceutical Preparations industry and within the Healthcare sector, were reflected in Emmaus Life Sciences Inc results which underperformed overall market.

Company's sequential top-line increase was 36.74% from the second quarter. Average annual sales rise for Emmaus Life Sciences Inc is -11.68%, while S & P 500's average yearly sales growth is 10.59% over the five years, including only Businesses with the fourth quarter 2025 Results.

EMMAW Growth Rates by Company's Segments

Segment Name
Y / Y
Sequential
Total
-47.61 %
17.08 %


Growth Rates of EMMAW's Income in the fourth quarter 2025


EMMAW Operating Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Operating Income Change (Q4 MRQ) -7.43 % 53.67 % 27.58 % 29.95 %
Sequential Operating Income Change (Q4 MRQ) - -27.23 % -17.34 % 4.5 %
Y / Y Operating Income Growth (Q4 TTM) - 48 % 37.03 % 14.37 %
Sequential Operating Income Growth (Q4 TTM) - 13.44 % 9.74 % 6.96 %
Operating Income 5 Year Avg. Change - 14.39 % 10.39 % 18.76 %


Income from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Income from Cont. Ops. Change (Q4 MRQ) - - - 21.83 %
Sequential Income from Cont. Ops. Change (Q4 MRQ) - - - 11.13 %
Y / Y Income from Cont. Ops. Change (Q4 TTM) - -59.4 % -25.13 % 16.46 %
Sequential Income from Cont. Ops. Change (Q4 TTM) - -10.61 % -6.43 % 6.05 %
Income from Cont. Ops. 5 Year Avg. Change - -0.55 % 0.17 % -28.52 %

EMMAW Net Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Net Income Growth (Q4 MRQ) - -26.27 % 16.75 % 21.56 %
Q / Q Net Income Growth (Q4 MRQ) - -43.4 % -34.6 % 11.12 %
Y / Y Net Income Change (Q4 TTM) - 27.23 % 32.74 % 16.59 %
Sequential Net Income Change (Q4 TTM) - 3.41 % 7.31 % 6.03 %
Net Income 5 Year Avg. Growth - 14.55 % 9.21 % 22.96 %

EMMAW's EPS Growth Rates


EPS from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS from Cont. Ops. Change (Q4 MRQ) - - - 21.83 %
Sequential EPS from Cont. Ops. Change (Q4 MRQ) - - - 11.13 %
Y / Y EPS from Cont. Ops. Change (Q4 TTM) - - - -
Sequential EPS from Cont. Ops. Change (Q4 TTM) - - - -99.7 %
EPS from Cont. Ops. 5 Year Avg. Growth - -10.79 % 0.17 % -28.52 %



EMMAW EPS Net Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS Net Growth (Q4 MRQ) - -29.53 % 16.75 % -28.52 %
Q / Q EPS Net Growth (Q4 MRQ) - -32.44 % -34.6 % 11.12 %
Y / Y EPS Net Change (for 12 months ending Q4 TTM) - - - -99.97 %
Sequential EPS Net Change (for 12 months ending Q4 TTM) - - - -99.87 %
EPS Net 5 Year Avg. Change - 14.55 % 9.21 % 22.96 %



Emmaus Life Sciences Inc reported bottom-line of $ -0.03 in the fourth quarter, compare to $ 0.03 in the same quarter a year ago. Major Pharmaceutical Preparations industry fell by -29.53%, while Healthcare sector increased by 16.75%, and overall market improved by 21.56%.

The company's sequential bottom-line increase was 36.74% from the second quarter. Average annual income per share rise for Emmaus Life Sciences Inc is -11.68%, while S & P 500's average yearly income per share growth is 22.96% over the five years, including only Businesses with the fourth quarter 2025 earnings results.

EMMAW Cash Flow Growth Rates


Free Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Free Cash Flow Change (Q4 MRQ) 1668.92 % -15.03 % -10.43 % 2 %
Sequential Free Cash Flow Change (Q4 MRQ) - -44.18 % -28.82 % 22.32 %
Y / Y Free Cash Flow Change (Q4 TTM) - 9.6 % 11.09 % 11.81 %
Sequential Free Cash Flow Change (Q4 TTM) - 1.75 % 1.93 % 2.41 %
Free Cash Flow 5 Year Avg. Change - 1.86 % 0.92 % 8.28 %

Net Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Net Cash Flow Change (Q4 MRQ) - - -90.24 % 1035.72 %
Sequential Net Cash Flow Change (Q4 MRQ) - - -99.01 % -
Y / Y Net Cash Flow Change (Q4 TTM) - -21.47 % -23.28 % -
Sequential Net Cash Flow Change (Q4 TTM) - -44.21 % -25.11 % -
Net Cash Flow 5 Year Avg. Change 0.55 % 29.88 % 6.46 % 1.06 %

Capital Expenditures Company Industry Sector S&P 500
Y / Y Capital Expenditures Change (Q4 MRQ) - 19.29 % 9.45 % 23.41 %
Sequential Capital Expenditures Change (Q4 MRQ) - 20.61 % 18.78 % 18.97 %
Y / Y Capital Expenditures Change (Q4 TTM) -46.15 % 20.54 % 10.57 % 23.88 %
Sequential Capital Expenditures Change (Q4 TTM) 0 % 11.3 % 6.56 % 7.02 %
Capital Expenditures 5 Year Avg. Change -41.82 % 8.94 % 9.18 % 14.72 %

Note
To view Detail Information & Trends click on Individual Category.
To see Industry, Sector or S&P 500 Performance, click on each Category respectivly, on the top of the Table.

For explanation of terms visit: Glossary
 







Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.